Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan + LDAC +/- Venetoclax in AML
NCT03634228Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of milademetan in acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Participants With a Response. Started Dec 2018; status: terminated.
02
Drugs
milademetan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03634228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634228.